Real-world insights into non-small cell lung cancer patients with MET exon 14 skipping mutations: A Swedish retrospective study from two university hospitals

被引：0

作者：

Skribek, M. ^{[1
]}

Brunnstrom, H. ^{[2
]}

Aricak, O. ^{[3
]}

Planck, M. ^{[4
]}

Jatta, K. ^{[5
]}

Oskarsdottir, G. N. ^{[4
]}

Naserhojati, H. ^{[6
]}

Haglund, F. ^{[7
]}

Ekman, S. ^{[8
]}

机构：

[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden

[2] Lund Univ, Div Pathol, Lund, Sweden

[3] Karolinska Univ Hosp, Dept Pathol & Cytol, Solna, Sweden

[4] Lund Univ, Div Oncol, Lund, Sweden

[5] Karolinska Univ Hosp Solna, Dept Pathol & Cytol, Solna, Sweden

[6] Karolinska Univ Hosp, Dept Pathol & Cytol, Huddinge, Sweden

[7] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden

[8] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1302

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1179P

引用

页码：S1087 / S1087

页数：1

共 50 条

[41] Tepotinib for advanced non-small-cell lung cancer with MET exon 14 skipping mutations
Blaszkowska, M.
Specht-Szwoch, Z.
Dziadziuszko, R.
ESMO OPEN, 2022, 7 (02)
[42] Biomarker Testing Patterns and Treatment Outcomes in Patients With Advanced Non-Small Cell Lung Cancer and MET Exon 14 Skipping Mutations
Kolaei, F. A. Zadeh Vosta
Cai, B.
Kanakamedala, H.
Kim, J.
Doban, V.
Zhang, S.
Shi, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S16 - S16
[43] The landscape of MET exon 14 skipping mutations in non-small cell lung cancer patients identified by next-generation sequencing
Chen Shi
Gao Ning
Zong Qinglan
CANCER RESEARCH, 2024, 84 (06)
[44] Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer
Li, Wen-Feng
Kang, Jin
Zhang, Xu-Chao
Jian, Su
Chen, Huajun
Wang, Zhen
Wang, Bin-Chao
Zhou, Qing
Tu, Hai-Yan
Wu, Yi-Long
Yang, Jin-Ji
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[45] Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
Minne, Rachel
Luo, Natalie
Traynor, Anne M.
Huang, Minxuan
De Tullio, Luisina
Godden, Jen
Stoppler, Melissa Conrad
Kimple, Randall J.
Baschnagel, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] Real-world outcomes comparison between the MET inhibitors (METi) capmatinib and tepotinib in patients with stage IV non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutation
Correia, Guilherme Sacchi de Camargo
Lou, Yanyan
Zhao, Yujie
Li, Shenduo
Ernani, Vinicius
Leventakos, Konstantinos
Mansfield, Aaron Scott
Parikh, Kaushal
Dimou, Anastasios
Manochakian, Rami
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[47] Updated molecular analysis of MET exon 14 skipping mutations (METex14) in non-small cell lung cancer (NSCLC)
Marks, Jennifer Aline
Gandhi, Nishant
Halmos, Balazs
Ramalingam, Suresh S.
Bazhenova, Lyudmila
Marmarelis, Melina Elpi
Xiu, Joanne
Walker, Phillip
Oberley, Matthew James
Ma, Patrick C.
Liu, Stephen V.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non -small cell lung cancer?
Pruis, Melinda A.
von der Thusen, Jan H.
Dubbink, Hendrikus Jan
ANNALS OF TRANSLATIONAL MEDICINE, 2020, 8 (22)
[49] Analysis of MET exon 14 skipping mutations in non-small cell lung cancer (NSCLC) by histology and specific mutation.
Marks, Jennifer Aline
Yin, Jun
Halmos, Balazs
Bazhenova, Lyudmila
Ramalingam, Suresh S.
Marmarelis, Melina Elpi
Xiu, Joanne
Walker, Phillip
Oberley, Matthew James
Ma, Patrick C.
Liu, Stephen V.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
Zheng, Difan
Wang, Rui
Ye, Ting
Yu, Su
Hu, Haichuan
Shen, Xuxia
Li, Yuan
Ji, Hongbin
Sun, Yihua
Chen, Haiquan
ONCOTARGET, 2016, 7 (27) : 41691 - 41702

← 1 2 3 4 5 →